Literature DB >> 15282392

Effect of oral bisphosphonates on bone mineral density and body composition in adult patients with cystic fibrosis: a pilot study.

S P Conway1, B Oldroyd, A Morton, J G Truscott, D G Peckham.   

Abstract

BACKGROUND: Approximately two thirds of adult patients with cystic fibrosis have reduced bone mineral density and up to one quarter have osteoporosis at one or more sites. Any bone mineral deficits are likely to be exacerbated in patients following lung transplantation by their immunosuppressive regimen. Vertebral collapse and rib fractures will impair the ability to cough and the efficacy of physiotherapy treatments.
METHODS: Patients attending the Leeds Regional Adult Cystic Fibrosis Unit with either osteopenia or osteoporosis on dual energy x ray absorptiometry (DXA) scanning were offered treatment with oral bisphosphonates after exclusion of abnormal vitamin D, calcium, or phosphate levels, abnormal thyroid function, or hypogonadism. Those declining treatment or patients with a normal initial DXA scan formed the control group. A second DXA scan was performed after a mean of 2.4 years in the treatment group and 2.9 years in the non-treatment group. Patients in the active group were asked to complete a short questionnaire detailing their adherence to treatment.
RESULTS: The medians of the differences in annual changes in bone parameters between treatment and control groups showed significant differences in bone mineralisation in favour of the treatment group at the lumbar spine (L2-L4), the femoral neck, and for total body measurements. There were no significant differences in weight, height, or body composition in either patient group. Most treated patients stated that they adhered to treatment most of the time.
CONCLUSION: Treatment with oral bisphosphonates may improve bone mineralisation in adult patients with cystic fibrosis. The results of this pilot study need to be further explored in a randomised controlled trial.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15282392      PMCID: PMC1747108          DOI: 10.1136/thx.2002.002568

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  27 in total

Review 1.  Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis.

Authors:  S C Manolagas
Journal:  Endocr Rev       Date:  2000-04       Impact factor: 19.871

2.  Anomalies in dual energy X-ray absorptiometry measurements of total-body bone mineral during weight change using Lunar, Hologic and Norland instruments.

Authors:  P Tothill; M A Laskey; C I Orphanidou; M van Wijk
Journal:  Br J Radiol       Date:  1999-07       Impact factor: 3.039

3.  Bone histomorphometry in adult patients with cystic fibrosis.

Authors:  C S Haworth; A K Webb; J J Egan; P L Selby; P S Hasleton; P W Bishop; T J Freemont
Journal:  Chest       Date:  2000-08       Impact factor: 9.410

4.  Anomalies in the measurement of changes in bone mineral density of the spine by dual-energy X-ray absorptiometry.

Authors:  P Tothill; A Avenell
Journal:  Calcif Tissue Int       Date:  1998-08       Impact factor: 4.333

5.  A total body phantom for use with Lunar dual-energy X-ray absorptiometers.

Authors:  B Oldroyd; R Milner; A H Smith; M A Smith
Journal:  Appl Radiat Isot       Date:  1998 May-Jun       Impact factor: 1.513

6.  Bone mineral content and body composition in children and young adults with cystic fibrosis.

Authors:  R C Henderson; C D Madsen
Journal:  Pediatr Pulmonol       Date:  1999-02

7.  Osteoporosis and osteopenia in adults and adolescents with cystic fibrosis: prevalence and associated factors.

Authors:  S P Conway; A M Morton; B Oldroyd; J G Truscott; H White; A H Smith; I Haigh
Journal:  Thorax       Date:  2000-09       Impact factor: 9.139

8.  Bone density, body composition, and inflammatory status in cystic fibrosis.

Authors:  A A Ionescu; L S Nixon; W D Evans; M D Stone; V Lewis-Jenkins; K Chatham; D J Shale
Journal:  Am J Respir Crit Care Med       Date:  2000-09       Impact factor: 21.405

9.  Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis.

Authors:  R M Aris; J B Renner; A D Winders; H E Buell; D B Riggs; G E Lester; D A Ontjes
Journal:  Ann Intern Med       Date:  1998-02-01       Impact factor: 25.391

10.  Low bone mineral density in adults with cystic fibrosis.

Authors:  C S Haworth; P L Selby; A K Webb; M E Dodd; H Musson; R McL Niven; G Economou; A W Horrocks; A J Freemont; E B Mawer; J E Adams
Journal:  Thorax       Date:  1999-11       Impact factor: 9.139

View more
  4 in total

Review 1.  Diagnosis and treatment of endocrine comorbidities in patients with cystic fibrosis.

Authors:  Oranan Siwamogsatham; Jessica A Alvarez; Vin Tangpricha
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-10       Impact factor: 3.243

Review 2.  Bisphosphonates for osteoporosis in people with cystic fibrosis.

Authors:  Louise S Conwell; Anne B Chang
Journal:  Cochrane Database Syst Rev       Date:  2014-03-14

3.  Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial).

Authors:  Alexandra Papaioannou; Courtney C Kennedy; Andreas Freitag; George Ioannidis; John O'Neill; Colin Webber; Margaret Pui; Yves Berthiaume; Harvey R Rabin; Nigel Paterson; Alphonse Jeanneret; Elias Matouk; Josee Villeneuve; Madeline Nixon; Jonathan D Adachi
Journal:  Chest       Date:  2008-07-18       Impact factor: 9.410

4.  Evaluation of teriparatide for treatment of osteoporosis in four patients with cystic fibrosis: a case series.

Authors:  Oranan Siwamogsatham; Kelly Stephens; Vin Tangpricha
Journal:  Case Rep Endocrinol       Date:  2014-03-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.